Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Active Biotech AB (publ)
  6. News
  7. Summary
    ACTI   SE0001137985

ACTIVE BIOTECH AB (PUBL)

(ACTI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Active Biotech's partner NeoTX will host KOL webinar on overcoming check point Inhibitor resistance

07/08/2021 | 02:30am EDT

Lund, July 8 2021 - Active Biotech (Nasdaq Stockholm: ACTI) today provided  information that its partner in the naptumomab project, NeoTX will host a key opinion leader (KOL) webinar on overcoming checkpoint inhibitor resistance on Wednesday, July 14th at 10 am eastern time (ET)

The webinar will feature a presentation by KOL Mario Sznol, MD, Yale Cancer Center, who will discuss New Frontiers for Checkpoint Inhibitors in Immuno-Oncology. NeoTX's management will also give an update on their Tumor Targeted Superantigen (TTS) platform’s lead candidate, naptumomab estafenatox (naptumomab) in overcoming resistance. Naptumomab is being evaluated in combination with chemotherapy, checkpoint inhibitors and CAR T. Dr. Sznol and NeoTX management will be available to answer questions following the formal presentations.

See also neotx.com/press-releases for NeoTX’s communication and for registration for the event.

Since 2016, Active Biotech has a licensing agreement with NeoTX Therapeutics Ltd. for the worldwide development and commercialization of naptumomab for cancer therapy.

For further information, please contact:
Helén Tuvesson, CEO, +46 46 19 21 56, helen.tuvesson@activebiotech.com
Hans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com

This information was submitted for publication, through the agency of the contact person set out above, at 08.30 a.m. CET on July 8, 2021.


Active Biotech
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. The small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is advancing to phase II for treatment of non-infectious uveitis during second half of 2021.  Please visit www.

Active Biotech AB

(Corp. Reg. No. 556223-9227)
Scheelevägen 22, SE-223 63 Lund, Sweden
Tel: +46 (0)46 19 20 00

Attachment


Primary Logo


© GlobeNewswire 2021
All news about ACTIVE BIOTECH AB (PUBL)
10/20ACTIVE BIOTECH : and NeoTX today announce that the first patient has been enrolled in the ..
AQ
10/20Active Biotech and Neotx Announces That the First Patient Has Been Enrolled in the Phas..
CI
10/03ACTIVE BIOTECH : Tasquinimod clinical  development in multiple myeloma advances into combi..
AQ
10/03Active Biotech Announces Tasquinimod Clinical Development in Multiple Myeloma Advances ..
CI
08/31ACTIVE BIOTECH : Company presentation
PU
08/05ACTIVE BIOTECH : Interim Report Jan-Jun 2021
PU
08/05ACTIVE BIOTECH AB : Interim report January – June 2021
AQ
08/05Active Biotech AB Publ Reports Earnings Results for the Second Quarter Ended June 30, 2..
CI
07/08Active Biotech's partner NeoTX will host KOL webinar on overcoming check point Inhibito..
GL
07/05Active Biotech provides status update of its clinical naptumomab project
GL
More news
Financials
Sales 2020 6,73 M 0,78 M 0,78 M
Net income 2020 -32,2 M -3,76 M -3,76 M
Net cash 2020 24,2 M 2,82 M 2,82 M
P/E ratio 2020 -8,51x
Yield 2020 -
Capitalization 294 M 34,2 M 34,3 M
EV / Sales 2019 32,1x
EV / Sales 2020 37,2x
Nbr of Employees 8
Free-Float 60,3%
Chart ACTIVE BIOTECH AB (PUBL)
Duration : Period :
Active Biotech AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACTIVE BIOTECH AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Managers and Directors
Helén Tuvesson President & Chief Executive Officer
Hans Kolam Chief Financial Officer
Michael Shalmi Chairman
Helena Eriksson Chief Scientific Officer & Head-Research
Karl Peter Thelin Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ACTIVE BIOTECH AB (PUBL)-28.57%34
GILEAD SCIENCES, INC.14.98%83 993
BIONTECH SE251.28%69 162
WUXI APPTEC CO., LTD.25.77%65 142
REGENERON PHARMACEUTICALS17.86%59 196
VERTEX PHARMACEUTICALS-20.84%48 536